Success Metrics

Clinical Success Rate
27.3%

Based on 3 completed trials

Completion Rate
27%(3/11)
Active Trials
0(0%)
Results Posted
333%(10 trials)
Terminated
8(73%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_2
2
18%
Ph phase_1
8
73%

Phase Distribution

8

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

27.3%

3 of 11 finished

Non-Completion Rate

72.7%

8 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(3)
Terminated(8)

Detailed Status

Terminated8
Completed3

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
27.3%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (72.7%)
Phase 22 (18.2%)
Phase 31 (9.1%)

Trials by Status

terminated873%
completed327%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_1

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

NCT02457598
terminatedphase_3

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665
completedphase_1

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

NCT03010358
completedphase_2

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

NCT02983617
terminatedphase_1

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

NCT03225924
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02457598Phase 1

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Terminated
NCT05020665Phase 3

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Terminated
NCT03010358Phase 1

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Completed
NCT02983617Phase 2

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Completed
NCT03225924Phase 1

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Terminated
NCT01796470Phase 2

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Terminated
NCT03135028Phase 1

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Terminated
NCT02404220Phase 1

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated
NCT02343939Phase 1

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Terminated
NCT02521376Phase 1

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

Completed
NCT02568683Phase 1

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11